This page separates reported trial results from statistical interpretation. The numerical results presented here are restricted to the statistical analyses and trial information from the ClinicalTrials.gov record.
1. Trial at a Glance
ORIGIN was a randomized phase 3 factorial trial enrolling 12,537 participants with Diabetes Mellitus, Non-Insulin-Dependent. The registry reports four arms and evaluates insulin glargine versus standard care using cardiovascular and other clinical endpoints, while the factorial structure also incorporated omega-3 polyunsaturated fatty acids and placebo.
| Feature | ORIGIN |
|---|---|
| Trial name | The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) |
| Phase | Phase 3 |
| Condition | Diabetes Mellitus, Non-Insulin-Dependent |
| Design | Randomized, factorial |
| Masking | None |
| Primary purpose | Treatment |
| Enrollment | 12,537 |
| Primary endpoints | 2 binary endpoints registered; both analyzed as time-to-event outcomes |
| Results posted | Yes |
| Statistical analyses posted | 5 |
| Lead sponsor | Sanofi |
| ClinicalTrials.gov | NCT00069784 |
2. Clinical Question
The insulin-glargine component of ORIGIN asks whether initial insulin glargine, compared with standard care, changes the time to major cardiovascular events and other clinically relevant outcomes in the enrolled population.
Population
Participants with Diabetes Mellitus, Non-Insulin-Dependent enrolled in the phase 3 ORIGIN trial.
Intervention
Insulin glargine (HOE901), as identified in the registry.
Comparator
Standard Care.
Primary question
Does insulin glargine versus standard care change the occurrence of the two registered cardiovascular composite endpoints?
3. Trial Design
Understanding the factorial structure
A factorial design evaluates more than one intervention dimension within the same randomized trial. ORIGIN included four arms and lists insulin glargine, omega-3 PUFA, placebo, and a reusable pen device among its interventions. The statistical comparison reported here is specifically insulin glargine versus standard care; the ClinicalTrials.gov record does not provide a separate formal analysis of an interaction between the factorial components.
4. Endpoints
| Endpoint | Registry definition / time frame | Analysis reported |
|---|---|---|
| Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke | Number of participants with a first occurrence of one of the above events; from randomization until study cut-off date (median duration of follow-up: 6.2 years). Positively-adjudicated first events were reviewed by an Event Adjudication Committee kept blinded to group assignment. | Log-rank test; Cox proportional-hazards model; hazard ratio |
| Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF) | Number of participants with a first occurrence of one of the above events; from randomization until study cut-off date (median duration of follow-up: 6.2 years). | Log-rank test; Cox proportional-hazards model; hazard ratio |
| Total Mortality (All Causes) | From randomization until study cut-off date (median duration of follow-up: 6.2 years). | Cox proportional-hazards model; hazard ratio |
| Composite Diabetic Microvascular Outcome (Kidney or Eye Disease) | From randomization until study cut-off date (median duration of follow-up: 6.2 years). | Cox proportional-hazards model; hazard ratio |
| Incidence of Development of Type 2 Diabetes Mellitus in Participants With IGT and/or IFG | From randomization until the last follow-up visit or last OGTT (median duration of follow-up: 6.2 years). | Cochran-Mantel-Haenszel test; odds ratio |
The two registered primary endpoints are composite cardiovascular outcomes. Both are described in the registry as binary primary endpoints, but the posted formal analyses use the timing of the first event and therefore apply time-to-event methods.
5. Statistical Methodology
Intention-to-treat analysis
The primary endpoint analyses were based on the intent-to-treat (ITT) population, defined in the registry as all randomized participants. This means the efficacy comparison is anchored to randomized assignment rather than to whether participants remained compliant with the assigned treatment.
Log-rank test
The primary cardiovascular endpoints were compared using a log-rank test. For time-to-event data, the log-rank test evaluates whether the observed event-time experience differs between randomized groups while incorporating information from participants who are censored before the study endpoint occurs.
Cox proportional-hazards model
The treatment effect for the primary cardiovascular endpoints was reported as a hazard ratio estimated using Cox regression. The registry analysis text identifies stratification by double-blind treatment, baseline diabetes diagnosis, and previous cardiovascular event.
A hazard ratio below 1 indicates a lower estimated instantaneous event rate in the insulin-glargine group under the fitted model; a hazard ratio above 1 indicates a higher estimated instantaneous event rate.
Covariate adjustment
For total mortality and the composite diabetic microvascular outcome, the Cox model included treatment as a factor together with double-blind treatment (omega-3 PUFA, placebo), baseline diabetes diagnosis, and previous cardiovascular event as covariates. This is different from simply comparing crude event proportions: the model estimates the treatment hazard ratio while accounting for the specified covariates.
Cochran-Mantel-Haenszel analysis
The development of type 2 diabetes endpoint was analyzed with a Cochran-Mantel-Haenszel (CMH) test. The odds ratio was stratified by double-blind treatment (omega-3 PUFA or placebo) and previous cardiovascular event (yes or no).
Stratified analysis
Stratification appears repeatedly in the registry's statistical analysis text. For the primary cardiovascular endpoint, the log-rank analysis was stratified by double-blind treatment, baseline diabetes diagnosis, and previous cardiovascular event. For the diabetes-development endpoint, CMH stratification used double-blind treatment and previous cardiovascular event.
6. Primary Results
Primary Endpoint 1: Cardiovascular Death, Nonfatal MI, or Nonfatal Stroke
Hazard ratio for first occurrence
95% CI: 0.937–1.114 · P = 0.6273
Insulin glargine vs standard care; median duration of follow-up: 6.2 years.
| Primary endpoint | Insulin Glargine vs Standard Care |
|---|---|
| Effect measure | Hazard ratio |
| Hazard ratio | 1.022 |
| 95% CI | 0.937–1.114 |
| P-value | 0.6273 |
| Method | Log-rank test; Cox proportional-hazards model |
| Analysis population | Intent-to-treat; all randomized participants |
| Time frame | From randomization until study cut-off date; median duration of follow-up: 6.2 years |
The hazard ratio of 1.022 is slightly above 1. Under the reported Cox model, this corresponds to an estimated hazard that is 1.022 times that of standard care for the first occurrence of the composite endpoint. Put differently, the point estimate is very close to 1.
The estimate does not mean that insulin glargine caused a 2.2% increase in the probability of experiencing the endpoint. A hazard ratio is a relative time-to-event measure, not an absolute risk difference or a percentage of patients affected.
The 95% confidence interval, 0.937–1.114, spans 1. This indicates uncertainty that includes both a lower and higher hazard relative to standard care. The interval describes uncertainty around the estimated treatment effect; it is not a range containing the effects experienced by individual participants.
The P-value of 0.6273 is a measure of compatibility with the statistical testing framework under the null hypothesis. It is not a measure of the magnitude or clinical importance of the hazard ratio. The estimate, confidence interval, endpoint definition, censoring, and model assumptions all contribute to interpretation.
Because this is a Cox analysis, interpretation also depends on the proportional-hazards assumption. A single hazard ratio summarizes the relative event-rate experience through the fitted model; it should not automatically be interpreted as a constant relative risk at every time point.
Primary Endpoint 2: Cardiovascular Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalization for HF
Hazard ratio for first occurrence
95% CI: 0.972–1.109 · P = 0.2692
Insulin glargine vs standard care; median duration of follow-up: 6.2 years.
| Primary endpoint | Insulin Glargine vs Standard Care |
|---|---|
| Effect measure | Hazard ratio |
| Hazard ratio | 1.038 |
| 95% CI | 0.972–1.109 |
| P-value | 0.2692 |
| Method | Log-rank test; Cox proportional-hazards model |
| Analysis population | Intent-to-treat; all randomized participants |
| Time frame | From randomization until study cut-off date; median duration of follow-up: 6.2 years |
The hazard ratio of 1.038 is close to 1. Under the reported Cox model, the estimated instantaneous event rate for the broader cardiovascular composite was 1.038 times that of standard care.
It does not mean that the probability of the composite endpoint was exactly 3.8% higher. Hazard ratios describe relative event rates in a time-to-event model and cannot be converted directly into an absolute risk difference without additional information.
The 95% confidence interval of 0.972–1.109 includes 1 and is relatively close to the point estimate on both sides. It therefore includes values corresponding to a modestly lower as well as a modestly higher estimated hazard relative to standard care.
The P-value of 0.2692 does not quantify the size of the observed effect. It addresses the statistical evidence against the relevant null hypothesis under the prespecified testing framework. It should be read together with the hazard ratio and confidence interval rather than used as a standalone measure of treatment effect.
The registry specifies a stratified log-rank comparison and a Cox regression model, with treatment as a factor and stratification by double-blind treatment, baseline diabetes diagnosis, and previous cardiovascular event. These design features matter because the reported estimate is model-based rather than a simple ratio of two cumulative event percentages.
7. Secondary Endpoint Results
Total Mortality (All Causes)
Hazard ratio for all-cause mortality
95% CI: 0.899–1.076 · P-value not reported in the ClinicalTrials.gov record
The analysis was based on the ITT population, meaning all randomized participants were included regardless of compliance with the protocol. The Cox model included treatment as a factor, with double-blind treatment, baseline diabetes diagnosis, and previous cardiovascular event as covariates.
A hazard ratio of 0.983 is close to 1, so the point estimate represents only a small relative difference in the modeled hazard of death between randomized groups. The 95% CI of 0.899–1.076 includes 1, indicating that the uncertainty interval encompasses both modestly lower and modestly higher hazards relative to standard care.
The hazard ratio is not an absolute mortality difference and does not say that 1.7% fewer participants died. The confidence interval concerns the estimated model parameter, not individual patient outcomes. The registry analysis does not report a P-value for this secondary endpoint, so no additional hypothesis-test interpretation is appropriate here.
Composite Diabetic Microvascular Outcome (Kidney or Eye Disease)
Hazard ratio for first microvascular outcome
95% CI: 0.900–1.047 · P-value not reported in the ClinicalTrials.gov record
This secondary time-to-event endpoint was analyzed in the ITT population using a Cox proportional-hazards model. The model included treatment as a factor and adjusted for double-blind treatment, baseline diabetes diagnosis, and previous cardiovascular event.
The point estimate of 0.970 corresponds to an estimated hazard approximately 0.970 times that of standard care under the reported Cox model. The 95% CI of 0.900–1.047 includes 1, so the interval is compatible with a range of effects around the null value.
Again, this is a relative time-to-event measure, not a 3.0% absolute reduction in kidney or eye disease. The ClinicalTrials.gov record does not report a P-value for this secondary analysis, so the confidence interval and point estimate provide the available statistical description.
Development of Type 2 Diabetes Mellitus in Participants With IGT and/or IFG
Odds ratio for development of type 2 diabetes
95% CI: 0.58–0.91 · P-value not reported in the ClinicalTrials.gov record
| Feature | Reported analysis |
|---|---|
| Population | Subgroup of the ITT population without diabetes at randomization |
| Endpoint | Incidence of Development of Type 2 Diabetes Mellitus in Participants With IGT and/or IFG |
| Effect measure | Odds ratio |
| Estimate | 0.72 |
| 95% CI | 0.58–0.91 |
| Method | Cochran-Mantel-Haenszel test |
| Stratification | Double-blind treatment and previous cardiovascular event |
| Time frame | From randomization until the last follow-up visit or last OGTT; median duration of follow-up: 6.2 years |
An odds ratio of 0.72 means that the estimated odds of developing type 2 diabetes in the insulin-glargine group were 0.72 times the corresponding odds in the standard-care group, using the reported CMH analysis.
This does not mean that the probability of diabetes was exactly 28% lower. Odds and probabilities are related but are not interchangeable, particularly when the outcome is not rare. An odds ratio should therefore not be described as a risk ratio without the additional information needed to make that conversion.
The 95% CI of 0.58–0.91 lies below 1. This gives the reported estimate a confidence interval that does not include the null odds ratio of 1. The interval describes uncertainty around the estimated odds ratio, not the range of individual treatment responses.
The registry-reported analysis does not report a P-value. The appropriate interpretation is therefore based on the reported odds ratio, its confidence interval, the prespecified subgroup population, and the CMH stratification rather than assigning an unreported significance level.
8. Results Summary
| Endpoint | Effect measure | Estimate | 95% CI | P-value | Method |
|---|---|---|---|---|---|
| CV death, nonfatal MI, or nonfatal stroke | Hazard ratio | 1.022 | 0.937–1.114 | 0.6273 | Log-rank; Cox proportional-hazards |
| CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for HF | Hazard ratio | 1.038 | 0.972–1.109 | 0.2692 | Log-rank; Cox proportional-hazards |
| Total Mortality (All Causes) | Hazard ratio | 0.983 | 0.899–1.076 | Not reported | Cox proportional-hazards |
| Composite Diabetic Microvascular Outcome | Hazard ratio | 0.970 | 0.900–1.047 | Not reported | Cox proportional-hazards |
| Development of Type 2 Diabetes Mellitus in participants with IGT and/or IFG | Odds ratio | 0.72 | 0.58–0.91 | Not reported | Cochran-Mantel-Haenszel |
9. Statistical Methods Explained
Why were log-rank tests used for the primary cardiovascular endpoints?
The primary cardiovascular outcomes were defined by the first occurrence of clinical events after randomization and were followed until a study cut-off. This creates time-to-event data rather than simply a yes/no outcome observed at one fixed time. The log-rank test is designed to compare event-time distributions between randomized groups while incorporating censored observations.
What does a hazard ratio of 1.022 mean?
A hazard ratio of 1.022 is a model-based relative comparison of the estimated instantaneous event rates. It is close to 1, meaning the fitted treatment-effect estimate is close to the null value. It is not a 2.2% difference in cumulative probability and does not indicate that each individual participant had a 2.2% higher risk.
Why is the confidence interval important?
The confidence interval provides information about statistical precision that a point estimate alone cannot provide. For the first primary endpoint, the interval is 0.937–1.114. For the second, it is 0.972–1.109. Both intervals include the null hazard ratio of 1, showing that the reported estimates are compatible with effects on either side of that value under the statistical framework.
Why use a Cox proportional-hazards model as well as a log-rank test?
The two methods serve related but different purposes. The log-rank test provides a formal comparison of the time-to-event experience between groups, while the Cox model provides an estimated hazard ratio and can incorporate specified stratification or covariate information. In ORIGIN, the registry reports both methods for the primary cardiovascular analyses.
Why was a Cochran-Mantel-Haenszel test used for diabetes development?
The diabetes-development endpoint was analyzed as a categorical outcome using the CMH method. CMH analysis provides a stratified comparison of odds while accounting for specified strata. Here, the odds ratio was stratified by double-blind treatment and previous cardiovascular event.
Why does ITT analysis matter?
ITT analysis preserves the treatment comparison created by randomization. In ORIGIN, the primary analyses were based on all randomized participants. This means the estimated treatment effect reflects assignment to insulin glargine versus standard care rather than only the experience of participants who remained fully compliant with their assigned treatment.
10. Factorial Design and Its Statistical Implications
The registry identifies ORIGIN as a factorial randomized trial with four arms and lists insulin glargine, omega-3 PUFA, placebo, and a reusable pen device among its interventions.
| Design feature | Statistical meaning |
|---|---|
| Factorial design | More than one intervention component is evaluated within a shared randomized trial structure. |
| Four arms | The registry reports four treatment arms rather than a simple two-arm trial. |
| Insulin comparison | The posted analyses compare Insulin Glargine vs Standard Care. |
| Additional factor | The reported analyses identify double-blind treatment as omega-3 PUFA or placebo. |
| Interaction | The statistical analyses posted on ClinicalTrials.gov do not report a formal interaction estimate between the factorial treatment components. |
Factorial designs can be statistically efficient because multiple treatment questions can be investigated in one randomized population. The important qualification is that the validity of a main-effect interpretation can depend on the absence, or appropriate handling, of meaningful interaction between factors. Because the registry analyses do not report an interaction result, no conclusion about such an interaction should be inferred here.
11. Stratification and Covariate Adjustment
The ORIGIN analyses illustrate two related but distinct approaches to controlling for important variables: stratification and covariate adjustment.
| Endpoint | Adjustment / stratification reported |
|---|---|
| First primary cardiovascular composite | Log-rank stratified by double-blind treatment, baseline diabetes diagnosis, and previous cardiovascular event. |
| Second primary cardiovascular composite | Log-rank stratified by double-blind treatment, baseline diabetes diagnosis, and previous cardiovascular event; Cox regression used the corresponding stratification structure. |
| Total mortality | Cox model with treatment plus double-blind treatment, baseline diabetes diagnosis, and previous cardiovascular event as covariates. |
| Composite diabetic microvascular outcome | Cox model with treatment plus double-blind treatment, baseline diabetes diagnosis, and previous cardiovascular event as covariates. |
| Development of type 2 diabetes | CMH analysis stratified by double-blind treatment and previous cardiovascular event. |
The distinction is important. A stratified log-rank test compares event-time distributions while accounting for the strata. A Cox model can use stratification to allow different baseline hazards across strata, while covariates can enter the model directly as explanatory variables. These approaches should not be described as interchangeable mathematical operations.
12. Primary Endpoint Construction
Both primary endpoints are composite outcomes based on the first occurrence of specified clinical events. The first primary composite includes cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The second expands the composite by adding revascularization and hospitalization for heart failure.
Why use a composite?
A composite endpoint can capture several clinically relevant event types within one prespecified outcome, allowing time to the first qualifying event to become the analysis target.
Why first occurrence matters
The registry specifies that the primary endpoint counts the first occurrence. Repeated events therefore do not contribute in the same way as the first qualifying event.
Why adjudication matters
The first primary endpoint used positively adjudicated events reviewed by an Event Adjudication Committee that was blinded to treatment assignment.
Why composite interpretation requires care
A hazard ratio for a composite describes the combined endpoint. It does not by itself establish that every individual component has the same magnitude or direction of effect.
13. Confidence Intervals and P-values
The two primary analyses provide a useful example of why point estimates, confidence intervals, and P-values answer different statistical questions.
| Endpoint | Estimate | 95% CI | P-value |
|---|---|---|---|
| CV death / nonfatal MI / nonfatal stroke | HR 1.022 | 0.937–1.114 | 0.6273 |
| CV death / nonfatal MI / nonfatal stroke / revascularization / hospitalization for HF | HR 1.038 | 0.972–1.109 | 0.2692 |
The point estimate gives the fitted treatment effect. The 95% confidence interval describes uncertainty around that estimate under the statistical model and sampling framework. The P-value summarizes evidence against a null hypothesis under the specified testing framework.
No one of these quantities should be used as a substitute for the others. In particular, a P-value is not an effect-size measure, and a confidence interval is not a prediction interval for individual participants.
14. Multiplicity and the Two Primary Endpoints
ORIGIN registered two primary endpoints. The registry-reported analysis notes state that the total required number of first coprimary outcomes, 2200, was based on assumptions that a hazard reduction of 14-16% would be clinically significant, with the overall experiment-wise Type 1 error controlled at 5% and power of 80% for each outcome.
Why two primary endpoints matter
Multiple primary endpoints create a multiplicity issue because repeated confirmatory testing can otherwise increase the probability of a false-positive conclusion.
Prespecified error control
The registry analysis notes explicitly describe control of the overall experiment-wise Type 1 error at 5% with power of 80% for each outcome.
The same analysis notes indicate that approximately 12,500 participants were ultimately estimated to be needed to achieve the targeted number of events within the planned enrollment and treatment periods. The actual enrollment was 12,537.
15. Safety Results
The ClinicalTrials.gov record reports serious adverse events by arm for the insulin-glargine comparison.
| Safety measure | Insulin Glargine | Standard Care |
|---|---|---|
| Serious adverse events | 303 / 6231 | 232 / 6273 |
The reported safety figures are counts of affected participants relative to the number at risk. They are presented descriptively here because the ClinicalTrials.gov record does not provide a formal statistical comparison, confidence interval, or P-value for serious adverse events.
16. Analysis Populations and Missing Data
The ClinicalTrials.gov record explicitly identifies the intent-to-treat population for the reported efficacy analyses. Primary analyses were based on all randomized participants, and the total-mortality analysis explicitly states that participants were included regardless of compliance with the protocol.
| Population / issue | What the ClinicalTrials.gov record reports |
|---|---|
| Primary efficacy population | Intent-to-treat; all randomized participants |
| Total mortality | All randomized participants regardless of protocol compliance |
| Microvascular outcome | Intent-to-treat; all randomized participants |
| Diabetes-development analysis | Subgroup of the ITT population without diabetes at randomization |
| Missing-data / imputation strategy | Not specified in the registry-reported statistical-analysis fields |
Time-to-event methods naturally accommodate censoring when participants have not experienced the event by their last available follow-up. However, the ClinicalTrials.gov record does not specify an imputation method for missing observations, so no particular missing-data procedure should be attributed to ORIGIN beyond the analysis descriptions provided.
17. Why the Time-to-Event Framework Matters
The cardiovascular endpoints were followed from randomization until the study cut-off, with a median duration of follow-up of 6.2 years. That structure means the analysis is not simply a comparison of the number of participants who eventually experienced an event.
The survival function represents the probability of remaining free of the event beyond time t. Time-to-event methods use both event timing and censoring information rather than reducing every participant to a single fixed-time binary observation.
For a participant who has not experienced the endpoint by the end of available follow-up, the observation is censored rather than treated as an event. This distinction is fundamental to Kaplan-Meier estimation, log-rank testing, and Cox regression.
18. Statistical Interpretation of the Five Reported Effects
| Endpoint | What the estimate represents | Null value |
|---|---|---|
| CV death / MI / stroke | Relative hazard of first composite event under the Cox model | HR = 1 |
| CV death / MI / stroke / revascularization / HF hospitalization | Relative hazard of first broader composite event under the Cox model | HR = 1 |
| Total mortality | Relative hazard of death from any cause under the Cox model | HR = 1 |
| Diabetic microvascular outcome | Relative hazard of first kidney or eye disease outcome under the Cox model | HR = 1 |
| Development of type 2 diabetes | Relative odds of the categorical diabetes-development outcome under CMH stratification | OR = 1 |
The first four estimates are hazard ratios and should therefore be interpreted in a time-to-event framework. The fifth is an odds ratio and belongs to a different statistical framework. Treating all five estimates as though they were the same measure would obscure an important methodological distinction.
19. What the Hazard Ratios Do — and Do Not — Mean
The estimated hazard for the first primary composite was 1.022 for insulin glargine relative to standard care under the reported Cox model. This is close to the null value of 1.
It does not mean that 2.2% more participants experienced the endpoint, nor does it mean that each participant's individual risk increased by 2.2%.
The estimated hazard for the broader cardiovascular composite was 1.038 relative to standard care. This is again a model-based time-to-event measure close to 1.
It does not represent a 3.8% absolute increase in cumulative event probability.
The all-cause mortality estimate of 0.983 is close to the null value. The confidence interval of 0.899–1.076 describes uncertainty around that model estimate.
The microvascular outcome estimate of 0.970 indicates a modeled hazard slightly below 1. The 95% CI of 0.900–1.047 includes the null value.
20. Odds Ratio vs Hazard Ratio
ORIGIN provides a useful teaching example because its statistical analyses include both a hazard ratio and an odds ratio.
| Feature | Hazard ratio | Odds ratio |
|---|---|---|
| ORIGIN examples | CV composites, total mortality, microvascular outcome | Development of type 2 diabetes in participants with IGT and/or IFG |
| Analysis framework | Time-to-event | Categorical / stratified analysis |
| Reported method | Cox proportional-hazards model | Cochran-Mantel-Haenszel test |
| Null value | 1 | 1 |
| Core interpretation | Relative event hazard over follow-up under the fitted model | Relative odds of the outcome under the stratified analysis |
An odds ratio of 0.72 should not be casually rewritten as a hazard ratio of 0.72 or a risk ratio of 0.72. The mathematical objects are different, and the appropriate interpretation depends on the outcome definition and analysis design.
21. Limitations and Interpretation Issues
- Composite endpoints: each primary endpoint combines multiple event types. A single hazard ratio summarizes the composite and does not establish identical effects across every component.
- First-event framework: the primary analyses concern the first qualifying occurrence, so recurrent events are not represented in the same way as first events.
- Factorial design: interpretation of a main treatment comparison can depend on the relationship between the factorial intervention components. The registry-reported analysis does not report a formal interaction result.
- Hazard-ratio assumptions: Cox proportional-hazards estimates rely on a proportional-hazards framework. The ClinicalTrials.gov record does not report a diagnostic assessment of that assumption.
- Censoring: time-to-event methods depend on appropriate handling of censored observations. The registry fields do not provide the underlying censoring data.
- Secondary endpoints: the statistical analyses posted on ClinicalTrials.gov report effect estimates and confidence intervals for three secondary endpoints, but P-values are not provided for those analyses in the ClinicalTrials.gov record.
- Subpopulation analysis: the diabetes-development endpoint is restricted to participants without diabetes at randomization, rather than the entire ITT population.
- Safety comparison: serious adverse-event counts are reported by arm, but the ClinicalTrials.gov record does not include a formal statistical comparison.
- Missing-data strategy: the registry-reported analysis fields do not specify a particular imputation procedure, so no such method should be inferred.
- Generalizability: the analysis describes the randomized trial population recorded in the registry and should not automatically be generalized to populations outside the trial's eligibility framework.
22. Why This Trial Matters Statistically
ORIGIN is a useful teaching case because it combines several core methods in one randomized clinical-trial program: factorial allocation, ITT analysis, stratified log-rank testing, Cox proportional-hazards modeling, covariate adjustment, CMH analysis, hazard ratios, odds ratios, confidence intervals, and composite time-to-event endpoints.
| Concept | How it appears in ORIGIN |
|---|---|
| Randomization | 12,537 participants randomized in a phase 3 trial. |
| Factorial design | Four-arm factorial structure involving insulin glargine and other listed interventions. |
| ITT analysis | Primary analyses based on all randomized participants. |
| Time-to-event endpoints | Primary cardiovascular outcomes followed from randomization until study cut-off. |
| Log-rank test | Used for the two primary cardiovascular comparisons. |
| Cox model | Used to estimate hazard ratios for primary and secondary time-to-event endpoints. |
| Hazard ratio | Reported for both primary cardiovascular endpoints and two secondary time-to-event endpoints. |
| Stratified analysis | Used in log-rank and CMH analyses and incorporated into the cardiovascular Cox framework. |
| Covariate adjustment | Used in the Cox analyses of total mortality and diabetic microvascular outcome. |
| Odds ratio | Used for development of type 2 diabetes in participants with IGT and/or IFG. |
| Multiplicity | Two coprimary outcomes with overall experiment-wise Type 1 error controlled at 5%. |
| Confidence intervals | Reported for all five posted statistical analyses. |
23. Longitudinal Trial History
Trial start
The ORIGIN phase 3 trial began enrollment according to the registry.
Primary completion
The registry records primary completion in December 2011.
Mature time-to-event analysis
The registered primary cardiovascular endpoints and the reported secondary time-to-event outcomes use follow-up from randomization until study cut-off, with a median duration of follow-up of 6.2 years.
24. A Practical Reading Strategy for the ORIGIN Results
A statistically disciplined reading of ORIGIN starts with the randomized comparison and then moves through the analysis hierarchy.
- Identify the estimand: determine exactly which endpoint is being compared and whether it is a time-to-event or categorical outcome.
- Identify the population: confirm whether the analysis uses the ITT population or the specified subgroup without diabetes at randomization.
- Identify the method: distinguish log-rank/Cox analyses from the CMH analysis.
- Read the effect estimate: interpret the HR or OR according to its statistical definition.
- Read the confidence interval: assess the precision and whether the interval includes the null value.
- Read the P-value only in context: the P-value describes statistical evidence under the relevant hypothesis-testing framework; it does not measure effect size.
- Check the design: factorial structure, stratification, composite endpoints, and the ITT framework all affect interpretation.
25. Related Tutorials
Learn more about the methods used in this trial:
26. Related Statistical Calculators
27. Sources
- ClinicalTrials.gov: ORIGIN Trial, NCT00069784.
- PubMed: PMID 22686416.
- PubMed: PMID 22686415.
- PubMed: PMID 40490702.
- PubMed: PMID 38747213.
- PubMed: PMID 36854916.
Continue through the Clinical Biostats statistical methods
Connect the ORIGIN endpoints to deeper tutorials on survival analysis, factorial trials, stratified methods, confidence intervals, and treatment-effect estimation.
28. Record Summary
ORIGIN provides a rich statistical example of a large randomized phase 3 factorial trial. Its primary cardiovascular endpoints were analyzed using stratified log-rank testing and Cox proportional-hazards models in the ITT population, with hazard ratios of 1.022 and 1.038. Secondary analyses extended the same survival framework to total mortality and diabetic microvascular outcomes, while development of type 2 diabetes in participants with IGT and/or IFG was evaluated with a stratified Cochran-Mantel-Haenszel analysis and an odds ratio of 0.72. The trial therefore illustrates how randomized design, endpoint construction, stratification, time-to-event analysis, covariate adjustment, categorical analysis, confidence intervals, and multiplicity fit together in a clinical-trial statistical analysis.